In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy

Anderson, 1997, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev., 28, 5, 10.1016/S0169-409X(97)00048-3 Atkins, 1994, The incorporation and release of glucose oxidase and interleukin-2 from a bead formed macroporous hydrophilic polymer matrix, J. Biomater. Sci., Polym. Ed., 6, 651, 10.1163/156856294X00590 Bernsen, 1999, Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration, Cancer Treat. Rev., 25, 73, 10.1053/ctrv.1998.0115 Bezemer, 2000, Zero-order release of lysozyme from poly(ethylene glycol)/poly(butylene terephtalate) matrices, J. Controlled Release, 64, 179, 10.1016/S0168-3659(99)00127-3 Bittner, 1999, Degradation and protein release properties of microspheres prepared by biodegradable poly(lactide-co-glycolide) and ABA triblock copolymers: influence of buffer media on polymer erosion and bovine serum albumin release, J. Controlled Release, 60, 297, 10.1016/S0168-3659(99)00085-1 Cadée, 2002, Release of recombinant human interleukin-2 from dextran-based hydrogels, J. Controlled Release, 78, 1, 10.1016/S0168-3659(01)00483-7 Cadée, 2000, In vivo biocompatibility of dextran-based hydrogels, J. Biomed. Mater. Res., 50, 397, 10.1002/(SICI)1097-4636(20000605)50:3<397::AID-JBM14>3.0.CO;2-A Chellat, 2000, In vitro and in vivo biocompatibility of chitosan–xanthan polyionic complex, J. Biomed. Mater. Res., 51, 107, 10.1002/(SICI)1097-4636(200007)51:1<107::AID-JBM14>3.0.CO;2-F De Groot, 2002, Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model, Int. J. Cancer, 98, 134, 10.1002/ijc.10167 De Jong, 2000, Novel self-assembled hydrogels by stereocomplex formation in aqueous solution of enantiomeric lactic acid oligomers grafted to dextran, Macromolecules, 33, 3680, 10.1021/ma992067g De Jong, 2001, Biodegradable hydrogels based on stereocomplex formation between lactic acid oligomers grafted to dextran, J. Controlled Release, 72, 47, 10.1016/S0168-3659(01)00261-9 De Jong, 2001, Physically crosslinked dextran hydrogels by stereocomplex formation of lactic acid oligomers: degradation and protein release behaviour, J. Controlled Release, 71, 261, 10.1016/S0168-3659(01)00228-0 Den Otter, 1995, Therapy of bovine ocular squamous cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up, Cancer Immunol. Immunother., 41, 10, 10.1007/BF01788954 Den Otter, 1996, Optimal regimes for IL-2 tumour therapy, Int. J. Cancer, 66, 400, 10.1002/(SICI)1097-0215(19960503)66:3<400::AID-IJC22>3.0.CO;2-D Den Otter, 1998, Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients, J. Urol., 159, 1183, 10.1016/S0022-5347(01)63548-1 Den Otter, 1999, Local low-dose IL-2 therapy, Hepato-Gastroenterology, 46, 1280 Den Otter, 2002, Testing therapeutic potency of anticancer drugs in animal studies: a commentary, Regul. Toxicol. Pharm., 35, 266, 10.1006/rtph.2001.1522 Egilmez, 1998, Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model, Cancer Immunol. Immunother., 46, 21, 10.1007/s002620050455 Egilmez, 2000, In situ tumor vaccination with interleukin-12 encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity, Cancer Res., 60, 3832 Franssen, 1999, Degradable dextran hydrogels: controlled release of a model protein from cylinders and microspheres, J. Controlled Release, 60, 211, 10.1016/S0168-3659(99)00074-7 Golumbek, 1993, Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design, Cancer Res., 53, 5841 Hennink, 2002, Novel crosslinking methods to design hydrogels, Adv. Drug Deliv. Rev., 54, 13, 10.1016/S0169-409X(01)00240-X Hennink, 1997, Dextran hydrogels for the controlled release of proteins, J. Controlled Release, 48, 107, 10.1016/S0168-3659(97)00047-3 Hill, 2002, Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor—encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease, Cancer Res., 62, 7254 Hora, 1990, Controlled release of interleukin-2 from biodegradable microspheres, Biotechnology, 8, 755, 10.1038/nbt0890-755 Huland, 1995, In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumours, J. Cancer Res. Clin. Oncol., 121, 285, 10.1007/BF01209595 Jeong, 1997, Biodegradable block copolymers as injectable drug-delivery systems, Nature, 388, 860, 10.1038/42218 Johnston, 1992, Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice, Pharm. Res., 9, 425, 10.1023/A:1015815624334 Kedar, 1994, Delivery of cytokines by liposomes. I. Preparation and characterisation of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes, J. Immunother. Emphasis Tumor Immunol., 16, 47, 10.1097/00002371-199407000-00005 Lim, 2000, Stereocomplex formation between enantiomeric PLA-PEG-PLA triblock copolymers: characterisation and use as protein delivery microparticulate carriers, J. Appl. Polym. Sci., 75, 1615, 10.1002/(SICI)1097-4628(20000328)75:13<1615::AID-APP7>3.0.CO;2-L Lim, 2000, A new class of biodegradable hydrogels stereocomplexed by enantiomeric oligo (lactide) side chains of poly (HEMA-g-OLA)s, Macromol. Rapid Commun., 21, 464, 10.1002/(SICI)1521-3927(20000501)21:8<464::AID-MARC464>3.0.CO;2-# Liu, 1997, Controlled release of interleukin-2 for tumour immunotherapy using alginate/chitosan porous microspheres, J. Controlled Release, 43, 65, 10.1016/S0168-3659(96)01471-X Maas, 1989, Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2, Cancer Res., 49, 7037 Maas, 1991, Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour, Cancer Immunol. Immunother., 33, 389, 10.1007/BF01741599 Matsuoka, 1993, Immunotherapy by a slow delivery system of interleukin-2 in mice models, Acta Med. Okayama, 47, 79 Miyata, 1999, Preparation of an antigen-sensitive hydrogel using antigen–antibody bindings, Macromolecules, 32, 2082, 10.1021/ma981659g Morikawa, 1987, Enhancement of therapeutic effects of recombinant interleukin-2 on a transplantable rat fibrosarcoma by the use of a sustained release vehicle, pluronic gel, Cancer Res., 47, 37 Park, 1996, Biocompatibility issues of implantable drug delivery systems, Pharm. Res., 13, 1770, 10.1023/A:1016012520276 Petka, 1998, Reversible hydrogels from self-assembling artificial proteins, Science, 281, 389, 10.1126/science.281.5375.389 Qu, 2000, Novel pH-sensitive chitosan hydrogels: swelling behaviour and states of water, Polymer, 41, 4589, 10.1016/S0032-3861(99)00685-0 Shipanova-Kadiyala, 1998, Polymeric controlled delivery of IL-2 and doxorubicin against a murine melanoma model, Proc. Int. Symp. Control Rel. Bioact. Mater., 25, 984 Taniguchi, 1999, Self-aggregate nanoparticles of cholesteryl and galactoside groups-substituted pullulan and their specific binding to galactose specific lectin, RCA120, Macromol. Chem. Phys., 200, 1554, 10.1002/(SICI)1521-3935(19990601)200:6<1554::AID-MACP1554>3.0.CO;2-V Vaage, 1991, Immunotherapy of a mouse mammary carcinoma by sustained peritumor release of IL-2, Int. J. Cancer, 47, 582, 10.1002/ijc.2910470417 Wang, 1999, Hybrid hydrogels assembled from synthetic polymers and coiled–coil protein domains, Nature, 397, 417, 10.1038/16264